Mereo Biopharma Group Plc - ADR
XNAS:MREO 4:00:00 PM EDT
| Market Cap (Intraday) | 305.47M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $2.08 |
| 50-Day MA | $1.95 |
| 200-Day MA | $2.11 |
Mereo Biopharma Group Plc - ADR Stock, XNAS:MREO
1 Cavendish Place, 4th Floor, London, Greater London W1G 0QF
United Kingdom
Phone: +44.333.023.7300
Number of Employees: 33
Description
Mereo BioPharma Group Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. Its portfolio include Etigilimab (MPH-313), Alvelestat (MPH-966), Setrusumab (BPS-804), Navicixizumab (OMP-305B83), Acumapimod (BCT-197), and Leflutrozole (BGS-649). The company was founded by Denise Vera Scots-Knight, Charles Edward Sermon, Alastair Graham MacKinnon, and John P. Richard in March 10, 2015 and is headquartered in London, the United Kingdom.